Dermata Therapeutics financials
$1.13+0.89%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$7.8M | -$12.5M | -$8.0M | -$9.7M | -$7.9M |
| Net income | -$7.6M | -$12.3M | -$7.8M | -$9.6M | -$10.5M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-8.16 | $-80.32 | $-399.90 | $-2088.00 | $-5832.00 |
| EBITDA | -$7.8M | -$12.5M | -$8.0M | -$9.7M | -$7.9M |
| Operating cash flow | -$7.8M | -$11.2M | -$6.4M | -$8.8M | -$5.7M |
| Free cash flow | -$7.8M | -$11.2M | -$6.4M | -$8.8M | — |
| Diluted shares | 0.9M | 0.2M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $7.5M | $3.2M | $7.4M | $6.2M | $10.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $7.9M | $3.5M | $8.0M | $6.9M | $11.6M |
| Total liabilities | $1.6M | $2.0M | $1.6M | $922.6K | $1.5M |
| Shareholders' equity | $6.2M | $1.6M | $6.4M | $6.0M | $10.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology